Saltar al contenido
Merck
Todas las fotos(3)

Key Documents

View All Documentation

480789

Sigma-Aldrich

Bismuth(III) subsalicylate

99.9% trace metals basis

Sinónimos:

Bismuth oxysalicylate, Bismuth subsalicylate, Bismuth(III) salicylate basic

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(3)

About This Item

Fórmula lineal:
HOC6H4COOBiO
Número de CAS:
14882-18-9
Peso molecular:
362.09
EC Number:
238-953-1
MDL number:
MFCD00085368
UNSPSC Code:
12161600
PubChem Substance ID:
24871718
NACRES:
NA.22

Quality Level

100

assay

99.9% trace metals basis

reaction suitability

core: bismuth
reagent type: catalyst

mp

>350 °C (lit.)

SMILES string

O[Bi]1OC(=O)c2ccccc2O1

InChI

1S/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+3;/p-3

InChI key

ZREIPSZUJIFJNP-UHFFFAOYSA-K

General description

Bismuth(III) subsalicylate (BSS) is mainly used in bismuth-based medicines for treating gastrointestinal disorders and diarrhea.

Application

  • Use of ferric chloride to identify salicylate-containing poisons.: This study explores the use of ferric chloride to detect salicylate compounds, including Bismuth subsalicylate, highlighting its significance in toxicological screenings and emergency treatments. (Hoffman RJ et al., 2002).
  • Effect of pepper and bismuth subsalicylate on gastric pain and surface hydrophobicity in the rat.: Investigates the effects of Bismuth subsalicylate on gastric pain and stomach lining properties, providing insights into its gastroprotective mechanisms. (Lichtenberger LM et al., 1998).
  • The coccoid forms of Helicobacter pylori. Criteria for their viability.: Examines the effectiveness of Bismuth subsalicylate in targeting different morphological forms of Helicobacter pylori, contributing to its role in eradication therapies. (Bode G et al., 1993).
  • Bismuth therapy in gastrointestinal diseases.: A comprehensive review of the therapeutic applications of Bismuth subsalicylate in treating various gastrointestinal disorders, underscoring its pharmacological benefits and safety profile. (Gorbach SL, 1990).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

D W Bierer
Reviews of infectious diseases, 12 Suppl 1, S3-S8 (1990-01-01)
Pepto-Bismol, which contains bismuth subsalicylate (BSS) as the active ingredient, has been marketed in the United States for more than 80 years. In the gastrointestinal tract, BSS is converted to salicylic acid and insoluble bismuth salts. The salicylate portion of
Copolymerizations of e-Caprolactone and Glycolide A Comparison of Tin (II) Octanoate and Bismuth (III) Subsalicylate as Initiators.
Kricheldorf HR and Rost S.
Biomolecules, 6(3), 1345-1352 (2005)
M D Manhart
Reviews of infectious diseases, 12 Suppl 1, S11-S15 (1990-01-01)
This report demonstrates that bismuth subsalicylate (BSS) effectively inhibits growth of a number of bacterial strains known to cause diarrhea, including Escherichia coli, Salmonella, Shigella, and Campylobacter. Other bismuth salts and sodium salicylate, a hydrolysis product of BSS in the
Michael S Leib et al.
Journal of veterinary internal medicine, 21(6), 1185-1192 (2008-01-17)
Helicobacter pylori is a common cause of gastritis and peptic ulcers in humans. Many dogs, including those with gastritis and chronic vomiting, are infected with Helicobacter spp. Triple antimicrobial therapy will eradicate Helicobacter infection, improve gastritis, and reduce clinical signs.
Abdurrahman Kadayifci et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 23(1), 8-13 (2012-04-17)
Helicobacter pylori eradication rates with standard triple regimens are worsening, and alternative treatments are urgently needed in some populations. The present study aimed to compare the efficacy of bismuth-based quadruple and concomitant regimens. Consecutive Helicobacter pylori-positive patients with non-ulcer dyspepsia
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico